Secondary end points of phase 3 EMBARK in high-risk biochemical recurrence of prostate cancer: enzalutamide monotherapy vs leuprolide alone, 5-year OS 89.5% vs 87.2% (nominal P values); sexual health better preserved (HR 0.76).
RCT
Shore et al. Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points